GDF-8 Propeptide
GDF-8 propeptide is the natural inhibitory proregion of myostatin (GDF-8) that binds and neutralizes mature myostatin, studied for preventing muscle wasting in cachexia and muscular dystrophy models. It represents a biologically derived approach to myostatin inhibition with potential applications in muscle preservation.
Written by WhatPeptide Editorial Team · Last updated 2026-03-17
Half-life
Estimated hours in circulation; protein-dependent
Dosage range
Not established for humans; animal studies 1-10 mg/kg
Administration
Subcutaneous injection
Research level
Preliminary
How GDF-8 Propeptide works
GDF-8 propeptide non-covalently binds mature myostatin in the extracellular space, preventing it from engaging its activin type II receptors (ACVR2A/B) and initiating SMAD2/3-dependent transcriptional repression of muscle growth. In animal models of muscular dystrophy and cancer cachexia, local or systemic administration of the propeptide increased lean muscle mass and functional strength. Clinical translation is limited by bioavailability challenges and the potential immunogenicity of exogenous protein.
Also known as: Myostatin Propeptide, GDF8 inhibitor, Myostatin inhibitor peptide
Research relevance
Side effects & safety
Contraindications
Consult a healthcare provider before use if any of these apply to you.
Key studies
-
Lee SJ & McPherron AC — Regulation of myostatin activity
Propeptide directly sequesters mature myostatin in latent complex — NOT receptor blockade
PubMed 2001 -
Bogdanovich S et al. — Myostatin propeptide ameliorates dystrophic pathophysiology
Propeptide sequestration increases muscle mass in mdx mice
PubMed 2008
FAQ
What is GDF-8 Propeptide? + −
What is GDF-8 Propeptide researched for? + −
What are the side effects of GDF-8 Propeptide? + −
Is GDF-8 Propeptide FDA approved? + −
How is GDF-8 Propeptide administered? + −
Explore similar peptides
IGF-1 DES
Animal studies onlyGrowth Factor
A naturally occurring 67-amino-acid truncated variant of IGF-1 missing the N-terminal Gly-Pro-Glu tripeptide. First isolated from bovine colostrum and human brain. Approximately 10-fold more potent than full-length IGF-1 due to ~100-fold reduced binding to IGF binding proteins, resulting in greater free peptide bioavailability.
IGF-1 LR3
Moderate evidenceGrowth Factor
IGF-1 LR3 is a recombinant analog of insulin-like growth factor-1 engineered with an arginine substitution and 13 amino acid N-terminal extension to dramatically extend its plasma half-life and reduce IGF-binding protein affinity, enhancing its anabolic potency. It is studied for muscle hypertrophy, recovery acceleration, and tissue repair.
Myostatin
Strong evidenceGrowth Factor
The body's primary negative regulator of skeletal muscle mass — a TGF-β superfamily member encoded by the MSTN gene. Its amino acid sequence is 100% conserved across humans, mice, rats, chickens, and pigs. This is a research reagent, not a therapeutic; myostatin inhibitors (follistatin, trevogrumab) are the therapeutic approach.
PEG-MGF
Preliminary evidenceGrowth Factor
PEG-MGF is a PEGylated synthetic analog of mechano growth factor (MGF), an IGF-1 splice variant produced locally in response to mechanical loading, engineered with polyethylene glycol attachment to extend its in vivo half-life from minutes to days. It is studied for skeletal muscle repair, hypertrophy, and satellite cell activation. Placed on FDA Category 2 list (September 29, 2023) as 'Mechano growth factor pegylated (PEG-MGF).'